Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bexatamig · SAR-443579

Bispecific antibody · Immune activation, directed at CD123 (interleukin-3 receptor alpha) (IL3RA), NKp46 (natural cytotoxicity triggering receptor 1) (NCR1) and CD16 (Fc gamma receptor IIIa) (FCGR3A) · developed by Sanofi

Phase 1/2 Most advanced trial (none active)
SNY Developer

What is Bexatamig?

Bexatamig is a tri-specific natural killer cell engager that binds CD123 on tumor cells and simultaneously binds the activating NK cell receptors NKp46 and CD16. This brings CD123-expressing cells and NK cells together, stimulating NK cells to lyse CD123-expressing tumor cells. It is being studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
SAR-443579
Drug type
Bispecific antibody
Targets
CD123 (interleukin-3 receptor alpha) (IL3RA), NKp46 (natural cytotoxicity triggering receptor 1) (NCR1), CD16 (Fc gamma receptor IIIa) (FCGR3A)
Mechanism
Immune activation, directed at CD123 (interleukin-3 receptor alpha) (IL3RA), NKp46 (natural cytotoxicity triggering receptor 1) (NCR1) and CD16 (Fc gamma receptor IIIa) (FCGR3A)
Pathways
NK cell activation, NK cell-mediated tumor cell lysis
Therapy area
Oncology
Developer
Sanofi (SNY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
4NPQ7H99U6

Conditions studied

Acute Myeloid Leukemia

Other drugs acting on IL3RA / NCR1 / FCGR3A

More from Sanofi

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the SNY page.

Follow SNY, the company behind Bexatamig

See SNY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

SNY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.